Aktienanalyse zu Ovid Therapeutics Inc (OVID)OVIDOvid Therapeutics Inc

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ovid Therapeutics is not a good buy right now due to its current price of $2.15, which is significantly below the average analyst price target of $6, suggesting potential upside. However, the stock has experienced a 12.60% decline over the last 5 days and has a very low RSI of 28.869, indicating oversold conditions. The main risk is the negative earnings trend, with a forward P/E of 1.7918, indicating potential challenges in profitability moving forward.

4 analysts cover OVID: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.17.